Megestrol Shortage Update: What Patients Need to Know in 2026

If you take Megestrol acetate (Megace) for AIDS-related wasting, advanced breast cancer, or endometrial cancer, you may have already encountered empty pharmacy shelves or back-order notices. The Megestrol tablet shortage — officially logged by ASHP in mid-2025 — has been one of the more disruptive supply disruptions in the specialty medication space. Here's everything patients need to know right now.

What Did the Official Shortage Notice Say?

As of May 2025, the ASHP drug shortage database listed Megestrol acetate tablets as being in shortage. The shortage covered both the 20 mg and 40 mg oral tablet strengths. Three major manufacturers confirmed back orders at the same time:

Strides Pharma: 20 mg tablets (100-count) back ordered; estimated release late May 2025. 40 mg tablets (100-count and 500-count) back ordered; estimated late June 2025.

Major Pharmaceuticals: 40 mg tablets (unit-dose packs) back ordered; estimated mid-June 2025.

Teva Pharmaceuticals: 20 mg (100-count) and 40 mg (100-count) tablets back ordered; estimated mid-July 2025.

When all three major suppliers of a drug are simultaneously on back order, the ripple effect at the pharmacy level can last months beyond the stated resupply dates — because pharmacy distributors, wholesalers, and retail shelves all need to be restocked in sequence.

What About the Oral Suspension (Megace Liquid)?

The ASHP shortage notice focused on tablets. The oral suspension formulations — the 40 mg/mL suspension and the concentrated Megace ES (125 mg/mL) — have experienced separate, intermittent supply challenges. The oral suspension is the FDA-approved form for AIDS-related cachexia, while tablets are used for cancer indications. These formulations are not interchangeable without a new prescription.

Why Is This Happening Now?

Megestrol has been a generic drug for many years, which means low profit margins for manufacturers. This creates a fragile supply chain: when one manufacturer has a production or raw material issue, there's limited buffer in the system to absorb the gap. The U.S. generic drug market overall is experiencing record-high shortage numbers, driven by thin margins, manufacturing facility issues, and concentrated API sourcing from overseas suppliers.

How Does This Affect Patients on Megestrol?

The practical impact depends on how long you've been on Megestrol and your clinical situation. Patients who have been on Megestrol for several months or longer face the highest risk from abrupt discontinuation. Long-term use suppresses the hypothalamic-pituitary-adrenal (HPA) axis, and stopping suddenly can lead to adrenal insufficiency — a potentially serious condition with symptoms including severe fatigue, dizziness, low blood pressure, nausea, and vomiting.

If you're approaching running out of Megestrol, contact your prescriber before your supply runs out — not after. Your doctor can advise on whether a taper is appropriate and help identify available supply or alternatives.

What Should Patients Do Right Now?

Check how many doses you have left and call your prescriber now if you have fewer than a 2-week supply.

Ask your pharmacist to check multiple wholesalers for any available NDC numbers.

Try independent, specialty, and mail-order pharmacies — they often have different inventory than major chains.

Use medfinder to find which pharmacies near you currently have Megestrol in stock without spending hours on the phone.

Ask your prescriber about compounding pharmacies as a bridging option.

Will the Shortage Be Resolved Soon?

Manufacturer estimates often slide from the original dates, and the fact that multiple suppliers were affected simultaneously means full market restoration could take longer than the official estimates. The best strategy is to act proactively now — find available supply, secure what you can, and have your prescriber prepared with an alternative plan.

For a full action plan, read: How to Find Megestrol in Stock Near You (Tools + Tips).